Clinical Characteristics and Outcomes of AIDS-Related Burkitt Lymphoma in China : A Retrospective Single-Center Study
Objectives: Studies on the prognosis and risk stratification of patients with acquired immune deficiency syndrome (AIDS) - related Burkitt lymphoma (AR-BL) are rare. We aim to construct a novel model to improve the risk assessment of these patients. Methods: We retrospectively analyzed the clinical data of 34 patients over the past 10 years and the factors associated with progression-free survival (PFS) and overall survival (OS) were evaluated in univariate and multivariate Cox models. Then, the novel model consisting of screened factors was compared with the existing models. Results: With a 37-month median follow-up, the overall 2-year PFS and OS rates were 40.50% and 36.18%, respectively. The OS of patients who received chemotherapy was better compared with those without chemotherapy (P = .0012). Treatment with an etoposide, prednisone, oncovin, cyclophosphamide, and hydroxydaunorubicin-based regimen was associated with longer OS and PFS compared with a cyclophosphamide, doxorubicin, vincristine, and prednisone-based regimen (OS, P = .0002; PFS, P = .0158). Chemotherapy (hazard ratio [HR] = 0.075; 95% confidence interval [CI], 0.009-0.614) and Eastern Cooperative Oncology Group Performance Status (ECOG PS) 2 to 4 (HR = 4.738; 95% CI, 1.178-19.061) were independent prognostic factors of OS in multivariate analysis and we established a novel prognostic risk stratification model named GZ8H model with chemotherapy and ECOG PS. Conclusion: GZ8H showed better stratification ability than the international prognostic index (IPI) or Burkitt lymphoma IPI (BL-IPI). Furthermore, the C-index of the nomogram used to predict OS was 0.884 in the entire cohort and the calibration curve showed excellent agreement between the predicted and actual results of OS. No human immunodeficiency virus-related factors were found to be associated with OS and PFS of AR-BL patients in our study. Overall, the clinical characteristics and outcomes in AR-BL were shown and prognostic factors for OS and PFS were identified in this study.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Technology in cancer research & treatment - 23(2024) vom: 06. Jan., Seite 15330338231214236 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Rongqiu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
5J49Q6B70F |
|---|
| Anmerkungen: |
Date Completed 08.01.2024 Date Revised 07.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1177/15330338231214236 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366702742 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366702742 | ||
| 003 | DE-627 | ||
| 005 | 20240207232218.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/15330338231214236 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1283.xml |
| 035 | |a (DE-627)NLM366702742 | ||
| 035 | |a (NLM)38179657 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Rongqiu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Characteristics and Outcomes of AIDS-Related Burkitt Lymphoma in China |b A Retrospective Single-Center Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.01.2024 | ||
| 500 | |a Date Revised 07.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Objectives: Studies on the prognosis and risk stratification of patients with acquired immune deficiency syndrome (AIDS) - related Burkitt lymphoma (AR-BL) are rare. We aim to construct a novel model to improve the risk assessment of these patients. Methods: We retrospectively analyzed the clinical data of 34 patients over the past 10 years and the factors associated with progression-free survival (PFS) and overall survival (OS) were evaluated in univariate and multivariate Cox models. Then, the novel model consisting of screened factors was compared with the existing models. Results: With a 37-month median follow-up, the overall 2-year PFS and OS rates were 40.50% and 36.18%, respectively. The OS of patients who received chemotherapy was better compared with those without chemotherapy (P = .0012). Treatment with an etoposide, prednisone, oncovin, cyclophosphamide, and hydroxydaunorubicin-based regimen was associated with longer OS and PFS compared with a cyclophosphamide, doxorubicin, vincristine, and prednisone-based regimen (OS, P = .0002; PFS, P = .0158). Chemotherapy (hazard ratio [HR] = 0.075; 95% confidence interval [CI], 0.009-0.614) and Eastern Cooperative Oncology Group Performance Status (ECOG PS) 2 to 4 (HR = 4.738; 95% CI, 1.178-19.061) were independent prognostic factors of OS in multivariate analysis and we established a novel prognostic risk stratification model named GZ8H model with chemotherapy and ECOG PS. Conclusion: GZ8H showed better stratification ability than the international prognostic index (IPI) or Burkitt lymphoma IPI (BL-IPI). Furthermore, the C-index of the nomogram used to predict OS was 0.884 in the entire cohort and the calibration curve showed excellent agreement between the predicted and actual results of OS. No human immunodeficiency virus-related factors were found to be associated with OS and PFS of AR-BL patients in our study. Overall, the clinical characteristics and outcomes in AR-BL were shown and prognostic factors for OS and PFS were identified in this study | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AIDS-related Burkitt lymphoma | |
| 650 | 4 | |a ECOG PS | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a clinical characteristic | |
| 650 | 4 | |a prognosis | |
| 650 | 7 | |a Prednisone |2 NLM | |
| 650 | 7 | |a VB0R961HZT |2 NLM | |
| 650 | 7 | |a Cyclophosphamide |2 NLM | |
| 650 | 7 | |a 8N3DW7272P |2 NLM | |
| 650 | 7 | |a Vincristine |2 NLM | |
| 650 | 7 | |a 5J49Q6B70F |2 NLM | |
| 650 | 7 | |a Doxorubicin |2 NLM | |
| 650 | 7 | |a 80168379AG |2 NLM | |
| 700 | 1 | |a Zhao, Han |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Guanying |e verfasserin |4 aut | |
| 700 | 1 | |a Tao, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Xiaoping |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Lizhi |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Baolin |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Guan, Jialong |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Linghua |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Zhimin |e verfasserin |4 aut | |
| 700 | 1 | |a He, Haolan |e verfasserin |4 aut | |
| 700 | 1 | |a You, Hua |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Technology in cancer research & treatment |d 2002 |g 23(2024) vom: 06. Jan., Seite 15330338231214236 |w (DE-627)NLM12389655X |x 1533-0338 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2024 |g day:06 |g month:01 |g pages:15330338231214236 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/15330338231214236 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2024 |b 06 |c 01 |h 15330338231214236 | ||